NYT Declined Zyprexa Court Invitation_Secrecy’s Dangerous SideEffects
"When legal settlements allow companies to hide their mistakes, what we don't know can hurt us."
"When legal settlements allow companies to hide their mistakes, what we don't know can hurt us."
These illegal practices are the secret behind this toxic drug–Zyprexa– becoming a blockbuster seller.
Eli Lilly's latest Zyprexa settlement will not affect civil or criminal investigations pending over Zyprexa from state attorneys general and federal prosecutors, which are continuing.
Spread the word! See and pass along: "Zyprexa Sales Rep" posted on YouTube:
http://www.youtube.com/watch?v=nj0LZZzrcrs
The Texas whistleblower lawsuit against Johnson & Johnson promises to topple the house of cards upon which the public mental health system rests.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
State Attorney Generals are investigating the off-label marketing of Zyprexa–which, if documented is a federal crime.
The New York Times is calling for congressional hearings after the revelations that Eli LillyDocumented evidence reveal that Eli Lilly glossed over the debilitating hazards of Zyprexa–and aggressively marketed it to primary care physicians.
"Most off-label use occurs without scientific support."
The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
THE NEW YORK TIMES EXPOSE OF ELI LILLY SECRET ZYPREXA DOCUMENTS Part II.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."